Clinical trials: Difference, Individual
Healthy, Liver Diseases
A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906
This study is open to adults who have different levels of liver problems and adults who are healthy. People with or without overweight or obesity can take part. This study has 2 parts.
- Conditions
- Healthy, Liver Diseases, Obesity
- Trial name
- NCT05296733
- Testing
- BI 456906
- Where
- 13 sites in United States, Germany and 4 more
- Volunteers
- 82 people
- Sponsor
- Boehringer Ingelheim
Renal Insufficiency
A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Kidney Problems
This study is open to people with and without kidney problems. People can join the study if they are 18 years or older and have a body mass index (BMI) between 18.5 and 35 kg/m2.
- Trial name
- NCT05718843
- Testing
- BI 425809
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Overweight, Obesity
A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity
This study tests how well different doses of the medicine NNC0662-0419 help people living with overweight or obesity. The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating people living with…
- Trial name
- NCT07184632
- Testing
- NNC0662-0419
- Where
- 2 sites in United States
- Volunteers
- 224 people
- Sponsor
- Novo Nordisk A/S
Solid Tumors
A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
This study is open to adults aged 18 and over or above legal age with different types of recurrent advanced cancer (solid tumors) that have spread to other parts of the body and that are accessible for injection and biopsy.
- Trial name
- NCT07395258
- Testing
- BI 3923948, Ezabenlimab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body
The primary objective of this trial is to investigate the relative bioavailability of BI 655130 administered as two subcutaneous injections in the left and right periumbilical region compared to a single subcutaneous…
- Trial name
- NCT03617835
- Testing
- R - Low dose of BI 655130, T1 - Low dose of BI 655130, T2 - Low dose of BI 655130
- Where
- Belgium
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hepatitis A
Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old
This study is conducted among people aged 18-50 in Dandong City, an area with a high incidence of hepatitis A in recent years. 1000 qualified pariticipants with signed informed consent will be screened for anti-HAV antibodies by…
- Trial name
- NCT06058416
- Testing
- Healive (hepatitis A vacine(human diploid cell), inactivated)
- Where
- China
- Volunteers
- 1,092 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Overweight, Obesity
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity.
- Trial name
- NCT07395687
- Testing
- UBT251
- Where
- 3 sites in United States, Canada
- Volunteers
- 333 people
- Sponsor
- Novo Nordisk A/S
Solid Tumors
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
This study is open to adults with advanced cancer (solid tumours). People for whom previous treatment was not successful and for whom no other treatment options exist can join the study.
- Trial name
- NCT05327946
- Testing
- BI 770371, ezabenlimab
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 42 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy People to See How Zongertinib is Taken up Into the Blood When Given as Tablets Made by Two Different Manufacturers
The main objective of this trial is to establish the bioequivalence of zongertinib tablet from manufacturer 1 (Test, T) compared with zongertinib tablet from manufacturer 2 (reference, R) following oral administration.
- Trial name
- NCT06360081
- Testing
- Zongertinib manufacturer 1, Zongertinib manufacturer 2
- Where
- Germany
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy People to Test How 3 Different Formulations of BI 764198 Are Taken up in the Body and How This is Influenced by Food
This trial aims to investigate the relative bioavailability of three different oral formulations of BI 764198 and how this is influenced by food.
- Trial name
- NCT06955754
- Testing
- BI 764198, formulation 1, BI 764198, formulation 2, BI 764198, formulation 3
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Mild-to-moderate Psoriasis Vulgaris
Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris
The overall purpose of this study is to support the development of a DLX105 topical formulation for the indication mild to moderate psoriasis vulgaris.
- Trial name
- 2011-00500-15 (NCT01595997)
- Testing
- DLX105
- Where
- 2 sites in Austria, Germany
- Volunteers
- 20 people
- Sponsor
- Delenex Therapeutics AG
Overweight, Obesity
A Study to Test How Well Different and Multiple Doses of BI 3034701 Are Tolerated in People Living With Overweight or Obesity
The main objectives of this trial are to investigate safety, tolerability of alternative dose titration strategies and pharmacokinetics (PK) of BI 3034701 in participants with overweight / obesity and at least one weight related…
- Trial name
- NCT07754474
- Testing
- BI 3034701
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Boehringer Ingelheim
Obesity
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 different doses of NNC0519-0130. Participants will take 1-2 injections once a week.
- Trial name
- NCT06326060
- Testing
- NNC0519-0130, Tirzepatide
- Where
- 70 sites in United States, Australia and 1 more
- Volunteers
- 354 people
- Sponsor
- Novo Nordisk A/S
Pertussis (Whooping Cough), Diphtheria
A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)
the immunogenicity and safety of different dosages of adsorbed acellular pertussis (two-component) diphtheria-tetanus combined vaccine
- Conditions
- Pertussis (Whooping Cough), Diphtheria, Tetanus
- Trial name
- NCT07894055
- Testing
- Tdap vaccine
- Where
- China
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Solid Tumors
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
This study is open to adults with different types of advanced cancer (solid tumors) that are accessible for injection and/or biopsy.
- Trial name
- NCT05155332
- Testing
- BI 1831169, anti-PD-1 antibody
- Where
- 33 sites in United States, Australia and 8 more
- Volunteers
- 190 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Chinese People to Test How Different Doses of BI 1015550 Are Taken up in the Body
The main objectives of this trial are to investigate pharmacokinetics, safety and tolerability of BI 1015550 in Chinese healthy male and female subjects following administration of single doses.
- Trial name
- NCT05633862
- Testing
- BI 1015550
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body
The main objective of this trial is to investigate relative bioavailability of BI 456906 reference formulation (Formulation A) vs. BI 456906 test formulation (Formulation B2).
- Trial name
- NCT07071974
- Testing
- BI 456906 formulation A, BI 456906 formulation B2
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1
A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week
This study compares the new long-acting insulin 287 with the marketed insulin glargine for use in type 1 diabetes. The study will test how insulin is taken up in your blood, how long it stays there and how the blood sugar is…
- Trial name
- NCT03723772
- Testing
- Insulin icodec, IGlar U100
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- Novo Nordisk A/S
Healthy
A Study in Healthy People to Compare 3 Different Formulations of Apremilast Tablets Taken With or Without Food
The aim of this trial is to establish bioequivalence between EU-, US- and Japan-sourced Otezla® tablet formulations to assure comparability of results from Phase III trials of BI 730357 (new oral agent for treatment of psoriasis…
- Trial name
- NCT04811573
- Testing
- EU-sourced Otezla®, US-sourced Otezla®, Japan-sourced Otezla®
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Liver Diseases, Healthy
A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems
This study is open to adults between 18 and 80 years of age. People with a body mass index (BMI) between 18 and 42 kg/m^2 can take part. Women can only participate if they cannot get pregnant.
- Trial name
- NCT06692322
- Testing
- Zongertinib
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Boehringer Ingelheim